BNP Paribas Arbitrage SA boosted its stake in Omnicell, Inc. (NASDAQ:OMCL) by 58.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,093 shares of the company’s stock after purchasing an additional 7,033 shares during the quarter. BNP Paribas Arbitrage SA owned about 0.05% of Omnicell worth $975,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of OMCL. Turner Investments LLC acquired a new stake in Omnicell in the second quarter worth $181,000. Riverhead Capital Management LLC grew its holdings in Omnicell by 76.3% in the second quarter. Riverhead Capital Management LLC now owns 4,230 shares of the company’s stock worth $182,000 after purchasing an additional 1,830 shares during the period. Flinton Capital Management LLC grew its holdings in Omnicell by 74.6% in the second quarter. Flinton Capital Management LLC now owns 4,216 shares of the company’s stock worth $182,000 after purchasing an additional 1,802 shares during the period. Sei Investments Co. grew its holdings in Omnicell by 36.4% in the second quarter. Sei Investments Co. now owns 4,652 shares of the company’s stock worth $200,000 after purchasing an additional 1,242 shares during the period. Finally, Pinebridge Investments L.P. grew its holdings in Omnicell by 1.6% in the second quarter. Pinebridge Investments L.P. now owns 4,896 shares of the company’s stock worth $211,000 after purchasing an additional 76 shares during the period. Institutional investors and hedge funds own 99.81% of the company’s stock.

Omnicell, Inc. (NASDAQ:OMCL) opened at $52.30 on Friday. Omnicell, Inc. has a 12 month low of $31.85 and a 12 month high of $55.40. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.38.

Omnicell (NASDAQ:OMCL) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.42 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The firm had revenue of $186.78 million for the quarter, compared to analyst estimates of $192.45 million. During the same period last year, the firm earned $0.40 earnings per share. The business’s quarterly revenue was up 5.7% compared to the same quarter last year. equities research analysts forecast that Omnicell, Inc. will post 0.12 EPS for the current year.

In other Omnicell news, VP Peter J. Kuipers sold 3,532 shares of the firm’s stock in a transaction on Monday, October 2nd. The shares were sold at an average price of $50.96, for a total value of $179,990.72. Following the transaction, the vice president now directly owns 40,714 shares of the company’s stock, valued at $2,074,785.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Dan S. Johnston sold 14,613 shares of the firm’s stock in a transaction dated Friday, November 17th. The shares were sold at an average price of $47.81, for a total transaction of $698,647.53. Following the transaction, the executive vice president now directly owns 43,621 shares in the company, valued at $2,085,520.01. The disclosure for this sale can be found here. Insiders sold 39,944 shares of company stock worth $1,941,322 over the last ninety days. Insiders own 3.77% of the company’s stock.

A number of equities research analysts have commented on the stock. Cantor Fitzgerald raised their price target on shares of Omnicell to $58.00 and gave the stock an “overweight” rating in a report on Friday, October 27th. Oppenheimer restated a “buy” rating and issued a $55.00 price target on shares of Omnicell in a report on Thursday, October 19th. Benchmark raised their price objective on shares of Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a research note on Tuesday, September 5th. Craig Hallum reaffirmed a “buy” rating and issued a $62.00 price objective (up from $52.00) on shares of Omnicell in a research note on Monday, October 30th. Finally, Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a research note on Wednesday, November 1st. One investment analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $54.86.

ILLEGAL ACTIVITY NOTICE: This news story was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another publication, it was illegally copied and reposted in violation of United States & international trademark and copyright laws. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2017/12/02/bnp-paribas-arbitrage-sa-boosts-holdings-in-omnicell-inc-omcl.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Want to see what other hedge funds are holding OMCL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Omnicell, Inc. (NASDAQ:OMCL).

Institutional Ownership by Quarter for Omnicell (NASDAQ:OMCL)

Receive News & Stock Ratings for Omnicell Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell Inc. and related stocks with our FREE daily email newsletter.